What is claimed is:

1. A method of treating fibromyalgia syndrome (FMS) and/or physiological symptoms associated therewith in an animal subject, comprising administering to an animal subject suffering from FMS, an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein the milnacipran is not administered adjunctively with phenylalanine, tyrosine or tryptophan.

3. The method according to claim 1, wherein FMS is treated.

4. The method according to claim 1, wherein symptoms associated with FMS are treated.

5. The method according to claim 1, wherein the compound is adjunctively administered with antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, sedatives, or hypnotics.

6. The method according to claim 1, wherein the compound is adjunctively administered with neurontin, pregabalin, pramipexole, l-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, codeine, carbamazepine, sibutramine, amphetamine, valium, or ~~trazodone.~~

7. The method according to claim 1, wherein the animal subject is a human.

8. The method according to claim 1, wherein the amount administered is from about 25 mg to about 400 mg per day.

9. The method according to claim 1, wherein the milnacipran is formulated in a sustained release dosage formulation.

10. A method of treating pain in an animal subject, comprising administering to an animal subject suffering from pain, an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof.

11. The method according to claim 10, wherein the milnacipran is not administered adjunctively with phenylalanine, tyrosine or tryptophan.

12. The method according to claim 10, wherein the compound is adjunctively administered with antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, sedatives, or hypnotics.

13. The method according to claim 10, wherein the compound is adjunctively administered with neurontin, pregabalin, pramipexole, l-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, a tricyclic antidepressant, codeine, carbamazepine, sibutramine, amphetamine, valium, or trazodone.

14. The method according to claim 10, wherein the animal subject is a human.

15. The method according to claim 10, wherein the amount administered is from about 25 mg to about 400 mg per day.

16. The method according to claim 10, wherein the compound is formulated in a sustained release dosage formulation.

17. A method of treating chronic fatigue syndrome (CFS) and/or physiological symptoms associated therewith in an animal subject, comprising administering to an animal subject suffering from CFS, an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof.

18. The method according to claim 17, wherein the milnacipran is not administered adjunctively with phenylalanine, tyrosine or tryptophan.

19. The method according to claim 17, wherein the compound is adjunctively administered with antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, sedatives, or hypnotics.

20. The method according to claim 17, wherein the compound is adjunctively administered with neurontin, pregabalin, pramipexole, l-DOPA, amphetamine, tizanidine,

clonidine, tramadol, morphine, a tricyclic antidepressant, codeine, carbamazepine, sibutramine, amphetamine, valium, or trazodone.

21. The method according to claim 17, wherein the animal subject is a human.

22. The method according to claim 17, wherein the amount administered is from about 25 mg to about 400 mg per day.

23. The method according to claim 17, wherein the compound is formulated in a sustained release dosage formulation.

24. A kit comprising a milnacipran or a pharmaceutically acceptable salt thereof and instructions teaching a method of use according to any one of Claims 1, 10 or 17.

25. The kit of claim 24 in which the milnacipran or salt thereof is packaged in unit dosage form.

add B37

add C37